Skip to content

The development of a simulator-based driving test for glaucoma patients

The development of a simulator-based driving test for glaucoma patients - Driving performance of glaucoma patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35659
Enrollment
80
Registered
2011-12-19
Start date
2011-12-22
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma

Interventions

None listed

Sponsors

Oogziekenhuis Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: General: Age >= 18 years and = 3 points depressed at p=0.05 level or 1 point at p=0.01). VF defects must be reproducible on at least one occasion.

Exclusion criteria

Exclusion criteria: General: BCVA > 0.3 (LogMAR). Refractive error ouside -10.0 to +5.0 D range. Cataract surgery in previous 12 months. Previous refractive or vitreoretinal surgery. Evidence of diabetic retinopathy, diabetic macular edema, or other vitreo-retinal disease. Previous keratoplastic surgery. Because driving simulators have been associated with simulator adaptation syndrome (SAS), characterized by autonomic symptoms such as drowsiness, vertigo, or nausea during testing participants with a history of motion/simulator sickness will be excluded from this study. Control group: Glaucoma. IOP >= 22 mm Hg. Untreated occludable angle with iridolenticular contact or evidence of iridolenticular contact or peripheral anterior synechia. Presence of disc hemorrhage. Glaucoma group: Secondary glaucomas except pigmentary. Evidence of SAP VF abnormality consistent with other disease.

Design outcomes

Primary

MeasureTime frame
During the test, participants* driving performance (position and speed of the virtual vehicle, control inputs), will be recorded. High-end eye tracking (Smart-Eye) will be applied to record head position and rotation, gaze direction, eyelid opening and pupil size.

Secondary

MeasureTime frame
N.a.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)